WALTHAM, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class
therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for
the quarter ended March 31, 2018, and recent business highlights.
“I am pleased by our team’s many accomplishments in the first quarter of 2018, which keep Proteon on track for a
potential BLA filing in 2019,” said Timothy Noyes, President and Chief Executive Officer of Proteon. “Most importantly, we
completed enrollment in PATENCY-2, our ongoing Phase 3 trial of vonapanitase. We also completed our drug substance process
validation runs at Lonza’s facility in Visp, Switzerland, and executed a long term contract extension with Lonza for the commercial
supply of vonapanitase, an agreement that we believe reflects the strength of our relationship with Lonza and the robustness of our
manufacturing process.”
Recent Highlights for 2018
Enrollment completed in PATENCY-2, the second Phase 3 clinical trial of investigational
vonapanitase, in March 2018. PATENCY-2 is a multicenter, randomized, double-blind, placebo-controlled trial that treated 603
patients in the United States and Canada with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic
arteriovenous fistula for hemodialysis. The study’s co-primary endpoints are fistula use for hemodialysis and secondary patency
(i.e., time to fistula abandonment), each of which demonstrated improvements in PATENCY-1 using the same definitions as in
PATENCY-2. The Company expects to report top-line data from PATENCY-2 in March 2019. If PATENCY-2 is successful in showing
statistical significance (p≤0.05) on each of the co-primary endpoints, Proteon expects to file a Biologics License Application
(BLA) with the U.S. Food and Drug Administration (FDA) in the second half of 2019 and a Marketing Authorization Application (MAA)
with the European Medicines Agency (EMA) in 2020.
Successful completion of the three drug substance validation runs. The Company manufactured
three batches of vonapanitase’s active pharmaceutical ingredient (API) in the second half of 2017, each of which met the intended
release specifications in the first quarter of 2018. The Company expects to include documentation of the manufacturing process and
results from these validation runs in a potential BLA filing in the second half of 2019 if positive topline data from the PATENCY-2
trial is released earlier in 2019. The API manufacturing campaign was validated at commercial scale at Lonza Ltd.’s facility in
Visp, Switzerland.
Important amendment to the supply agreement with Lonza was signed, securing a potential long
term commercial supply of API for vonapanitase. Lonza has manufactured API for Proteon at its microbial manufacturing facility in
Visp, Switzerland since 2009. The amendment extends the term of the supply agreement until 2029.
Enrollment continues in a Phase 1 clinical trial of vonapanitase in patients with peripheral artery
disease (PAD). The multicenter, randomized, double-blind, placebo-controlled Phase 1 dose escalation trial is expected to
enroll 24 symptomatic PAD patients being treated with balloon angioplasty of an artery below the knee and to follow each patient
for up to seven months. Immediately following successful angioplasty, vonapanitase or placebo is delivered to the arterial wall
using the Mercator MedSystems Bullfrog® Micro-Infusion Catheter. The primary outcome measure of the trial is safety and the
secondary outcome measure is technical feasibility of study drug delivery via the catheter.
Key Milestones
- Complete enrollment of 24 patients in the PAD Phase 1 trial by the fourth quarter of 2018.
- Release top-line data from PATENCY-2 in March 2019.
Upcoming Events
- Presentation at the JMP Securities Life Science Conference June 20-21 in New York City, NY.
- Presentation by Keith Ozaki, M.D., at the Vascular Access Society of Americas (VASA) on May 12th in New Orleans,
Keith Ozaki M.D.
First Quarter 2018 Financial Results
Cash, cash equivalents and available-for-sale investments totaled $36.8 million as of March 31, 2018, compared
to $42.1 million as of December 31, 2017. The decrease was primarily driven by operational costs for the first three-month period
of 2018.
R&D expenses: Research and development expenses for the first quarter of 2018 were $4.1
million as compared to $4.2 million for the first quarter of 2017. The decrease in R&D expenses was due primarily to decreased
personnel expenses in the first quarter of 2018 as compared to the first quarter of 2017.
MG&A expenses: Marketing, general and administrative expenses for the first quarter of 2018
were $2.3 million as compared to $2.2 million for the first quarter of 2017. The increase in MG&A expenses was due primarily to
higher overhead and personnel expenses in the first quarter of 2018 as compared to the first quarter of 2017.
Net loss: Net loss for the first quarter of 2018 was $6.1 million as compared to $6.5 million
for the first quarter of 2017. Net loss included stock-based compensation expense of $0.8 million for the first quarter of 2018 and
$0.8 million for the first quarter of 2017.
Financial guidance: The Company expects that its cash, cash equivalents and available-for-sale
investments will be sufficient to fund its operations into the fourth quarter of 2019, based on the Company’s current operating
plan.
About Vonapanitase
Vonapanitase is an investigational drug intended to improve hemodialysis vascular access outcomes. Vonapanitase is applied in a
single administration and is currently being studied in a Phase 3 clinical trial in patients with chronic kidney disease (CKD)
undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis. Vonapanitase has received Breakthrough
Therapy, Fast Track and Orphan Drug designations from the FDA, and Orphan Medicinal Product designation from the European
Commission, for hemodialysis vascular access indications. In addition, vonapanitase may have other surgical and endovascular
applications in diseases or conditions in which vessel injury leads to blockages in blood vessels and reduced blood flow. Proteon
is currently conducting a Phase 1 clinical trial of vonapanitase in patients with peripheral artery disease (PAD).
About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the
development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug
intended to improve hemodialysis vascular access outcomes. Proteon is evaluating vonapanitase in patients with CKD undergoing
surgical creation of a radiocephalic arteriovenous fistula. Proteon is also evaluating vonapanitase in a Phase 1 clinical trial in
patients with PAD. For more information, please visit www.proteontx.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are, or may be deemed to be, "forward-looking statements" as defined in the Private
Securities Litigation Reform Act of 1995. In some cases, these forward-looking statements can be identified by the use of
forward-looking terminology, including the terms “estimates,” “anticipates,” "expects,” “plans,” "intends,” “may,” or “will,” in
each case, their negatives or other variations thereon or comparable terminology, although not all forward-looking statements
contain these words. These statements, including the number of patients to be enrolled in and the timing of enrollment in the
Company’s ongoing Phase 1 clinical trial of vonapanitase in patients with peripheral artery disease (PAD), when the Company expects
to release top-line data from the PATENCY-2 trial, whether and when the Company may submit a Biologics License Application (BLA) in
the United States or Marketing Authorization Application (MAA) in Europe, the effect or benefit of vonapanitase in patients with
chronic kidney disease (CKD), whether vonapanitase improves fistula use for hemodialysis or secondary patency, the potential
surgical and endovascular applications for vonapanitase, including PAD, the sufficiency of the Company’s cash, cash-equivalents and
available-for-sale investments to fund the Company’s operations into the fourth quarter of 2019, and those relating to future
events or our future financial performance or condition, involve substantial known and unknown risks, uncertainties and other
important factors that may cause our actual results, levels of activity, performance or achievements to differ materially from
those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors, including whether our
cash resources will be sufficient to fund the Company’s operating expenses and capital expenditure requirements for the period
anticipated; whether data from early nonclinical or clinical studies will be indicative of the data that will be obtained from
future clinical trials; whether vonapanitase will advance through the clinical trial process on the anticipated timeline and
warrant submission for regulatory approval; whether such a submission would receive approval from the U.S. Food and Drug
Administration or equivalent foreign regulatory agencies on a timely basis or at all; and whether the Company can successfully
commercialize and market its product candidates, are described more fully in our Annual Report on Form 10-K for the year ended
December 31, 2017, as filed with the Securities and Exchange Commission (“SEC”) on March 14, 2018, and the Company’s subsequent
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as filed with the SEC, particularly in the sections titled “Risk
Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations.” In light of the significant
uncertainties in the Company’s forward-looking statements, no person should place undue reliance on these statements or regard
these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives
and plans in any specified time frame, or at all. The forward-looking statements contained in this press release represent the
Company’s estimates and assumptions only as of the date of this press release and, except as required by law, the Company
undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information,
future events or otherwise after the date of this press release.
| |
|
|
|
|
| Proteon Therapeutics, Inc. |
| Consolidated Balance Sheet Data |
(In thousands)
|
| |
|
|
|
|
| |
|
March 31, |
|
December 31, |
| |
|
2018 |
|
2017 |
| |
|
|
|
|
| Cash, cash equivalents and available-for-sale investments |
|
$ |
36,818 |
|
|
$ |
42,141 |
|
| |
|
|
|
|
| Prepaid expenses and other current assets |
|
|
1,215 |
|
|
|
1,339 |
|
| |
|
|
|
|
| Property and equipment, net and other non-current assets |
|
|
476 |
|
|
|
499 |
|
| |
|
|
|
|
| Total assets |
|
$ |
38,509 |
|
|
$ |
43,979 |
|
| |
|
|
|
|
| Accounts payable and accrued expenses |
|
$ |
9,020 |
|
|
$ |
9,240 |
|
| |
|
|
|
|
| Preferred Stock, common stock and additional paid-in-capital |
|
|
225,315 |
|
|
|
224,494 |
|
| |
|
|
|
|
| Accumulated deficit and accumulated other comprehensive income |
|
|
(195,826 |
) |
|
|
(189,755 |
) |
| |
|
|
|
|
| Total liabilities and stockholders’ deficit |
|
$ |
38,509 |
|
|
$ |
43,979 |
|
| |
|
|
|
|
| |
|
|
|
|
| Proteon Therapeutics, Inc. |
| Condensed Consolidated Statements of
Operations |
| (in thousands, except share and per share
data) |
| |
|
|
|
|
| |
|
|
| |
|
Three Months Ended March 31, |
| |
|
2018 |
|
2017 |
| Operating expenses: |
|
|
|
|
| Research and development |
|
$ |
4,071 |
|
|
$ |
4,246 |
|
| General and administrative |
|
|
2,294 |
|
|
|
2,234 |
|
| Total operating expenses |
|
|
6,365 |
|
|
|
6,480 |
|
| Loss from operations |
|
|
(6,365 |
) |
|
|
(6,480 |
) |
| Other income (expense): |
|
|
|
|
| Investment income |
|
|
92 |
|
|
|
32 |
|
| Other income (expense), net |
|
|
192 |
|
|
|
(50 |
) |
| Total other (expense) income |
|
|
284 |
|
|
|
(18 |
) |
| Net loss |
|
$ |
(6,081 |
) |
|
$ |
(6,498 |
) |
| Net loss per share attributable to common stockholders - basic and
diluted |
|
$ |
(0.34 |
) |
|
$ |
(0.39 |
) |
| Weighted-average common shares outstanding used in net loss per
share attributable to common stockholders - basic and diluted |
|
|
17,674,729 |
|
|
|
16,636,201 |
|
| |
|
|
|
|
Investor Contact
George Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer
781-890-0102
geldridge@proteontherapeutics.com
Media Contact
Ann Stanesa, Ten Bridge Communications
617-230-0347
proteon@tenbridgecommunications.com
